Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Ιωάννα Ανδρεάδου, Καθηγήτρια ,Ιατρική Σχόλη, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Ευάγγελος Τέρπος, Καθηγητής, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Μαρία Γαβριατοπούλου, Επίκουρη Καθηγήτρια, Ιατρική Σχόλη, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Original Title:
Η χρήση των εκλεκτικών αναστολέων επαναπρόσληψης σεροτονίνης κατά την κύηση: δεδομένα από αναφορές ασφάλειας
Translated title:
Use of selective serotonin reuptake inhibitors in pregnancy: data from safety reports
Summary:
Pharmacotherapy of depression poses a major challenge for both the doctor and the expectant mother, due to concerns that the drugs may harm the fetus. However, recent research suggests that depression and stress itself may have equally devastating effects on the mother and the newborn. Unfortunately, in this field conducting high quality randomized double-blind studies is not feasible and scientific knowledge is largely based on data from pharmacovigilance and from clinical studies that are inevitably susceptible to systematic errors. The object of this research work is to investigate reports of adverse events following pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs), which is the most commonly used class of antidepressants. The objectives are firstly to attempt a comparative study and evaluation of SSRIs regarding their safety and secondly to investigate whether pharmacovigilance data support the notion, commonly used in clinical studies, of including all SSRIs in a single category regarding the risk of their use in pregnancy. Present results show that SSRIs differ significantly in terms of their security profile. While data on fluvoxamine are scarce, citalopram appears to increase the probability of congenital impairments in sensory organs and paroxetine appears to increase the probability of congenital heart defects, whereas sertraline appears to have the most favorable safety profile. Importantly, present data do not support the notion of SSRIs being a homogeneous category regarding their safety in pregnancy and cast doubt on the validity of those studies that group them together in relevant studies of safety in pregnancy.
Main subject category:
Health Sciences
Keywords:
Depression, Antidepressants, Pregnancy, Safety, Pharmacovigilance
Number of references:
137
File:
File access is restricted only to the intranet of UoA.
Kokras Nikolaos Master.pdf
2 MB
File access is restricted only to the intranet of UoA.
